Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Multiple myeloma represents the second most common hematological malignancy.VELCADE is a
small molecule to treat human malignancies. Its anti-neoplastic effect invovles several
distinct mechanisms including inhibition of cell growth. Patients who have relapsed or are
refractory to therapy, the standard of care is now VELCADE based on the results of previous
clinical trials.